1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649
    Meeting Abstract

    Elimova, E.; Shitara, K.; Moehler, M. H.; Ajani, J. A.; Shen, L.; Garrido, M.; Gallardo, C.; Wyrwicz, L. S.; Yamaguchi, K.; Cleary, J. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01
    Meeting Abstract

    Fan, J.; Bekaii-Saab, T. S.; Aldrighetti, L. A.; Bridgewater, J. A.; Ferrone, C. R.; Harding, J. J.; Ikeda, M.; Knox, J. J.; Wang, J. L.; Kayhanian, H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • GEMINI-Hepatobiliary: A phase 2 study of novel first-line immuno-oncology-based treatments in patients with advanced hepatobiliary cancers
    Meeting Abstract

    Zhou, J.; Cheng, A. L.; Ikeda, M.; Lim, H. Y.; Akce, M.; Qin, S.; Oh, D. Y.; Chan, S. L.; Xiang, J.; Qu, X.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Shitara, K.; Van Cutsem, E.; Lordick, F.; Enzinger, P. C.; Ilson, D. H.; Shah, M. A.; Xu, R. H.; Lonardi, S.; Yamaguchi, K.; Hung, Y. P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites
    Meeting Abstract

    Fakih, M.; Bullock, A. J.; Schlechter, B. L.; Tsimberidou, A. M.; Messersmith, W. A.; Pimentel, A.; Balmanoukian, A. S.; Sanborn, R. E.; Segal, N. H.; Bockorny, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM)
    Meeting Abstract

    Tsang, E. S.; Shi, Q.; Olive, K. P.; Collisson, E. A.; Dixon, J. G.; Cusnir, M.; Winograd, R.; Botta, G. P.; Wadlow, R. C.; Shergill, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies
    Meeting Abstract

    Park, Y. H.; Cortes, J.; Modi, S.; Hurvitz, S. A.; Bianchini, G.; Iwata, H.; Shitara, K.; Siena, S.; Goto, Y.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202
    Meeting Abstract

    Muro, K.; Chin, K.; Maron, S. B.; Braiteh, F. S.; Mitani, S.; Hara, H.; Kuboki, Y.; Mulcahy, M. F.; Baranda, J. C.; Gardner, F. P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer-Evaluating radiation, ablation, and surgery (ERASur)
    Meeting Abstract

    Miller, E. D.; Hitchcock, K.; Shi, Q.; Dixon, J. G.; Gholami, S.; White, S. B.; Wu, C.; Goulet, C. C.; Jee, K. W.; Wright, C. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma
    Meeting Abstract

    O'Reilly, E. M.; Wainberg, Z. A.; Fisher, G. A. Jr; Wolff, R. A.; Ko, A. H.; O'Hara, M. H.; Spencer, C. N.; Yu, J. X.; Da Silva, D. M.; Padron, L. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save